CYVNY

0.02800.00%
KE

Katherine Ellen-Danielle Connell

Independent Non-Executive Director

Ms. Katherine Ellen-Danielle Connell, also known as Kathy, is Non-Executive Director of Avecho Biotechnology Limited from April 26, 2024. She is Independent Non-Executive Director of Ceryvyn Therapeutics Limited (formerly known as Opthea Limited) from November 15, 2024. She is Non-Executive Director of Proto Axiom Pty Ltd. She is healthcare and life sciences leader with deep and broad investment and licensing expertise, delivering a solid track record of value creating deals across pharmaceuticals, medtech, vaccines consumer and digital healthcare for some of the world’s largest companies. She has held senior executive leadership positions in biotechnology, pharmaceutical, medical device and consumer health sectors specialising in business development, licensing, acquisitions and venture investment, as well as having worked in healthcare and lifesciences executive search and management consulting. Her tenure at Johnson & Johnson and Sanofi, Kathy led external innovation investment, licensing and acquisition across. She co-founded Medicines Australia’s Pharmaceutical Australia Inclusion Group (PAIG). She was awarded BioMelbourne Network’s Woman of the Year in 2018 for her leadership in supporting Australia’s high priority strategic growth sectors of biotech, medtech and pharmaceuticals. Seh is advisory board member for Flinders University Medical Device Research Institute. Kathy is a registered psychologist, holding tertiary degrees and qualifications in Applied Science, Psychology, Mediation and Law as well as being a Graduate of the Australian Institute of Company Directors.

Positions